Search Results

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition.

Prometheus Laboratories Inc. announced the execution of provider agreements with three large regional health plans to facilitate access to PredictrPK®, precision-guided biologic testing, and other Prometheus testing services to the participating health plans and their respective members.

Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Prometheus Biosciences, Inc. (Nasdaq: RXDX) today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.

Prometheus Biosciences, Inc. announced that management will conduct fireside chats at the following healthcare conferences.

Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, reported financial results for the quarter ended March 31, 2023.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 10:40 AM ET.

Prometheus Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering.

Prometheus Biosciences, Inc. (Nasdaq: RXDX) today reported financial results for the quarter and full-year ended December 31, 2022 and highlighted recent corporate progress.